雄激素受体剪接变异体7在去势抵抗性前列腺癌中的作用及其临床意义  

Role of androgen receptor splice variants 7 in castration-resistant prostate cancer and its clinical significance

作　　者：张烨 王磊[1] 张璐[1] 钟云萍[1] 刘修恒[1] ZHANG Ye;WANG Lei;ZHANG Lu;ZHONG Yunping;LIU Xiuheng(Department of Urology,Renmin Hospital of Wuhan University,Hubei Province,Wuhan430060,China)

机构地区：[1]武汉大学人民医院泌尿外科

出　　处：《中国医药导报》2020年第1期46-49,共4页China Medical Herald

基　　金：中央高校基本科研业务费专项资金项目（2042019kf0091）

摘　　要：去势抵抗性前列腺癌(CRPC)是经过初次持续内分泌治疗后仍然进展的前列腺癌。CRPC的发生和发展机制极其复杂,目前尚未完全研究清楚,但雄激素受体(AR)信号的持续激活仍是重要因素。雄激素受体剪接变异体7(AR-V7)是AR重要的变异体之一,其与CRPC发生、发展存在密切联系,在促进AR的再活化、肿瘤的生长转移以及耐药性的产生中起着重要作用,与内分泌治疗的敏感性和总体存活率降低相关,是一种潜在评价指标,深入研究AR-V7与CRPC的关系,不仅可以指导现阶段CRPC的用药,还可以为CRPC的治疗提供新的途径和方向。Castration-resistant prostate cancer(CRPC) is a prostate cancer that progresses after initial sustained endocrine therapy. The mechanism of CRPC occurrence and development is extremely complicated and has not been fully studied yet, but the continuous activation of androgen receptor(AR) signal is still an important factor. Androgen receptor splice variants 7(AR-V7) is one of the most important variants of AR. Many studies have shown that it is closely related to the development of CRPC, promoting AR reactivation, tumor growth and metastasis. It plays an important role in the development of drug resistance, and is associated with the sensitivity of endocrine therapy and the overall survival rate. It is a potential evaluation index. In-depth study of the relationship between AR-V7 and CRPC can not only guide the current use of CRPC, it can also provide new ways and directions for the treatment of CRPC.

关 键 词：前列腺癌 去势抵抗性前列腺癌 雄激素受体 雄激素受体剪接变异体7 临床意义 

分 类 号：R737.25[医药卫生—肿瘤]